Evolving Management Options for Alopecia Areata: Clinical Burden, Cost Effective Care, and Emerging Treatments

Join us for a Satellite Symposium conducted at the 2022 ASHP Midyear Clinical Meeting and Exhibition!

Monday, December 5, 2022
Check-in: 10:45 AM PST
Presentation: 11:30 AM – 1:00 PM PST

VENUE

South Pacific H, Lower Level
Mandalay Bay North Convention Center
3950 S Las Vegas Boulevard
Las Vegas, Nevada 89119

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from Pfizer, Inc.

PROGRAM OVERVIEW

The hair loss that occurs in patients with alopecia areata (AA) imposes a significant psychological burden on the over 300,000 US individuals affected by the disease each year. Traditionally, AA management has been limited to the off-label use of various treatments, many of which can be associated with significant side effects and often provide only limited relief. As understanding of AA pathophysiology has evolved, we have witnessed the development of a number of novel targeted therapies. Foremost among these are multiple JAK inhibitors, one of which has just been approved by the FDA.

Join our esteemed faculty for a review of the recently approved and emerging JAK inhibitor therapies for AA. Complemented with case-based learning and faculty roundtable discussions, this symposium is designed to help providers achieve better outcomes for their patients with AA.

TARGET AUDIENCE

This educational activity has been designed for community pharmacists, specialty pharmacists, and healthcare professionals in allergy, immunology, dermatology, and managed care who manage patients with AA.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Outline the pathophysiology and clinical burden of AA
  • Review clinical data on emerging agents for AA to determine their potential placement in the treatment landscape
  • Identify the pharmacoeconomic factors associated with emerging AA therapies

FACULTY

Brett King, MD
Associate Professor of Dermatology
Yale School of Medicine
New Haven, Connecticut

Eric Cannon, PharmD, FAMCP
Chief Pharmacy Officer
SelectHealth
Murray, Utah

PROVIDER STATEMENT

This CME activity for ACCME credit is provided by Integrity Continuing Education, Inc.

This CE activity for ACPE credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc.

ACCREDITATION

Physician Continuing Education

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Integrity Continuing Education, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.

Pharmacist Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Credit Designation

Global Education Group designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0530-9999-22-110-L01-P)

This is a knowledge-based activity.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit, participants must attend the activity, complete the posttest questions, submit the credit application, and complete the online evaluation per the instructions given at the meeting. Pharmacists must check the CPE Monitor within 60 days of the activity.

CONTACT INFORMATION

Integrity Continuing Education, Inc.

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

Global Education Group

For information about the ACPE accreditation of this activity, please contact Global at (303) 395-1782 or cme@globaleducationgroup.com.

FEE INFORMATION

There is no registration fee for attending this symposium; however, seating is limited. Registration for this event is for planning purposes only and seating will be available on a first-come, first-served basis.

AMERICANS WITH DISABILITIIES ACT

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Integrity Continuing Education, Inc. prior to the live event at (855) 835-4004.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Name of Faculty

Reported Financial Relationship

Brett King, MD Advisory boards, Consultant: AbbVie, AltruBio Inc, Almirall, AnaptysBio, Arena Pharmaceuticals, Bioniz Therapeutics, Bristol Myers Squibb, Concert Pharmaceuticals Inc, Equillium, Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Otsuka/Visterra Inc, Pfizer, Inc., Regeneron Pharmaceuticals, Sanofi Genzyme, TWi Biotechnology Inc, Viela Bio
Speaker: AbbVie, Eli Lilly and Company, Incyte, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme
Investigator: AnaptysBio, Arena Pharmaceuticals, Concert Pharmaceuticals Inc, Eli Lilly and Company, Pfizer, Inc.
Eric Cannon, PharmD, FAMCP Has no real or apparent conflicts of interest to disclose.

 

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager Reported Financial Relationship
Olivia Benevento Nothing to disclose
Lindsay Borvansky Nothing to disclose
NyQwayah Brown Nothing to disclose
Ashley Cann Nothing to disclose
Stefani Chiarolanza Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Brittany Puster Nothing to disclose
Lauren Sinclair Nothing to disclose
Patima Tanapat, PhD Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Food and beverage are no longer provided at Midday Symposia. This ASHP policy considers the varied internal policies of commercial supporters related to the Physician Payments Sunshine Act. You are welcome to bring your lunch to the session.

Agenda

10:45 AM EST Check-in
11:30 AM – 12:30 PM PST Case-Based & Roundtable Discussion
12:30 PM – 1:00 PM PST Question & Answer Session